What was the revenue generated by Royalty Pharma in the 2021-Q1 quarter? 
ioned that in the conversations they've had with world governments, World Bank, how capitals flow around the globe in the investment community.
And so when these markets open and here markets not only geographically, but also think about it from an industry perspective, the fact that MSCI creates indexes attracts many billions of dollars of capital into that space. And I gave the example of maybe an early stage biotech index or an oncology index or you name it, it can be many others then what is likely to happen over time is that as products are created like the ETFs or mutual funds to focus on that specific theme or new market, capital flows and then companies end up getting additional capital to fund their research. So it's a very interesting phenomenon, but one that we -- and like just the whole -- the development of thematic indexes and life sciences is also going to make the whole life sciences investment opportunity more understandable, more accessible to investors, and this will attract capital. So it's quite interesting from that perspective.
And I think it -- so I'll let Chris answer this other question about impact to life sciences from big trends.
Chris Hite -- Vice Chairman
Sure. Thanks, Pablo. And, Andrew, thanks for the question. I think as it relates specifically to the intellectual property waiver, we don't see that as something that's going to impact our business long term.
I know the ideas have been floated, and obviously, there's global pandemic. And from a compassionate perspective, you want to get as many vaccine doses around the world as you possibly can and there's probably more efficient ways -- actually, just transfer excess doses once the supply is there as opposed to trying to waive intellectual property. And with know-how, obviously, these vaccines are very difficult to make, the manufacturer. So I think it's probably more efficient ways to get the vaccines around the world than just waiving intellectual property.
We don't see the need for compassion use right now as impacting intellectual property laws going forward, so we don't see that as impacting our business going forward.
Operator
There are no further questions. I'd like to turn the call back over to Pablo Legorreta for concluding remarks.
Pablo Legorreta -- Founder and Chief Executive Officer
Sure, operator. Thank you. Thank you to everyone on the call for your continuing interest in Royalty Pharma. My team and I look forward to continuing to share our progress with you.
If you have any follow-up questions, please feel free to reach out to George. And thank you for joining the call, and I hope everyone has a good week. Thank you.
Operator
[Operator signoff]
Duration: 61 minutes
Call participants:
George Grofik -- Senior Vice President, Head of Investor Relations, and Communications
Pablo Legorreta -- Founder and Chief Executive Officer
Marshall Urist -- Executive Vice President, Co-Head of Research, and Investments
Jim Reddoch -- Executive Vice President, Co-Head of Research and Investments, and Chief Scientific Officer
Terry Coyne -- Executive Vice President, Chief Financial Officer
Chris Neyor -- J.P. Morgan -- Analyst
Geoff Meacham -- Bank of America Merrill Lynch -- Analyst
Terence Flynn -- Goldman Sachs -- Analyst
Greg Gilbert -- Truist Securities -- Analyst
Kathy Miner -- Cowen and Company -- Analyst
David Risinger -- Morgan Stanley -- Analyst
Mike DiFiore -- Evercore ISI -- Analyst
Andrew Baum -- Citi -- Analyst
Chris Hite -- Vice Chairman
More RPRX analysis
All earnings call transcripts
ioned that in the conversations they've had with world governments, World Bank, how capitals flow around the globe in the investment community.
And so when these markets open and here markets not only geographically, but also think about it from an industry perspective, the fact that MSCI creates indexes attracts many billions of dollars of capital into that space. And I gave the example of maybe an early stage biotech index or an oncology index or you name it, it can be many others then what is likely to happen over time is that as products are created like the ETFs or mutual funds to focus on that specific theme or new market, capital flows and then companies end up getting additional capital to fund their research. So it's a very interesting phenomenon, but one that we -- and like just the whole -- the development of thematic indexes and life sciences is also going to make the whole life sciences investment opportunity more understandable, more accessible to investors, and this will attract capital. So it's quite interesting from that perspective.
And I think it -- so I'll let Chris answer this other question about impact to life sciences from big trends.
Chris Hite -- Vice Chairman
Sure. Thanks, Pablo. And, Andrew, thanks for the question. I think as it relates specifically to the intellectual property waiver, we don't see that as something that's going to impact our business long term.
I know the ideas have been floated, and obviously, there's global pandemic. And from a compassionate perspective, you want to get as many vaccine doses around the world as you possibly can and there's probably more efficient ways -- actually, just transfer excess doses once the supply is there as opposed to trying to waive intellectual property. And with know-how, obviously, these vaccines are very difficult to make, the manufacturer. So I think it's probably more efficient ways to get the vaccines around the world than just waiving intellectual property.
We don't see the need for compassion use right now as impacting intellectual property laws going forward, so we don't see that as impacting our business going forward.
Operator
There are no further questions. I'd like to turn the call back over to Pablo Legorreta for concluding remarks.
Pablo Legorreta -- Founder and Chief Executive Officer
Sure, operator. Thank you. Thank you to everyone on the call for your continuing interest in Royalty Pharma. My team and I look forward to continuing to share our progress with you.
 If you have any follow-up questions, please feel free to reach out to George. And thank you for joining the call, and I hope everyone has a good week. Thank you.
Operator
[Operator signoff]
Duration: 61 minutes
Call participants:
George Grofik -- Senior Vice President, Head of Investor Relations, and Communications
Pablo Legorreta -- Founder and Chief Executive Officer
Marshall Urist -- Executive Vice President, Co-Head of Research, and Investments
Jim Reddoch -- Executive Vice President, Co-Head of Research and Investments, and Chief Scientific Officer
Terry Coyne -- Executive Vice President, Chief Financial Officer
Chris Neyor -- J.P. Morgan -- Analyst
Geoff Meacham -- Bank of America Merrill Lynch -- Analyst
Terence Flynn -- Goldman Sachs -- Analyst
Greg Gilbert -- Truist Securities -- Analyst
Kathy Miner -- Cowen and Company -- Analyst
David Risinger -- Morgan Stanley -- Analyst
Mike DiFiore -- Evercore ISI -- Analyst
Andrew Baum -- Citi -- Analyst
Chris Hite -- Vice Chairman
More RPRX analysis
All earnings call transcripts